Yurpeak is the second tirzepatide brand from Eli Lilly to be launched in the country after receiving approval from the drug regulator.

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market ...

The Mumbai-based drugmaker, in a regulatory filing, said it has the rights to distribute and promote Yurpeak, the second anti ...

U.S.-based Eli Lilly & Co. (LLY) and Danish drug maker Novo Nordisk (NVO) are vying to capture a large portion of India’s ...

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market ...

Commenting on the launch, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said, "The launch of Yurpeak marks a transformative moment in the fight against obesity and type 2diabetes ...

Cipla has launched Yurpeak (tirzepatide), a once-weekly injectable for adults with obesity and type 2 diabetes. As the second brand of Lilly's tirzepatide in India, it will be available via ...

Cipla Limited on Wednesday launched Yurpeak (tirzepatide) in India, a once-weekly injectable therapy for managing obesity and type 2 diabetes, two of the country’s most pressing health challenges.

If you regularly deal with eczema, rosacea, very dry skin, or barrier damage, Dr. Shokeen advises using toner pads with extra ...

Hand gestures are finally here for the Pixel Watch 4, enabling multiple one-handed actions. Here's how to use them and how well they work right now.

When you think of focus apps, your mind probably jumps to heavyweights like Notion or Todoist since these feature databases, ...

By integrating Gemini into my note-taking workflow, I have turned a basic app into a high-powered personal assistant. From ...